Clarity Research
NSE: CAPLINPNT · Monitoring Dashboard · Updated Q3 FY26
Caplin Point Laboratories · Living Document
Quarterly Monitoring Dashboard — Post-Investment Tracking
The thesis is only as good as the discipline to monitor it. This document tracks the specific signals that confirm, challenge, or break the investment case — updated every quarter after results.
How To Use This Document
Update this dashboard within 48 hours of each quarterly result. Check every metric against its target threshold. Any metric in amber requires an explanation in the notes column — is it a one-time blip or a structural trend? Two consecutive amber quarters on the same metric triggers a formal thesis review. Any red metric triggers an immediate review. This is not a sell signal by itself — it is a signal that the thesis needs to be re-argued from scratch before the next market open.
01
Current Quarter Scorecard
Q3 FY26 · October–December 2025
Revenue (₹ Cr)
543
Target: >520 · YoY: +10%
On Track
EBITDA Margin
35.0%
Target: >30% · Floor: 27%
On Track
PAT (₹ Cr)
166
Target: >155 · YoY: +19%
On Track
TTM EPS (₹)
80.74
FY26E: ~₹88–92
On Track
US Revenue (annualised)
~$8.7M
Target: $15M by Q2 FY27
Building
Liquid Assets (₹ Cr)
2,459
Floor: >₹1,500 Cr
On Track
ANDA Approvals (cumul.)
55
Target: +8–12/year
On Track
Promoter Holding
70.6%
Floor: >65% · Watch: <68%
On Track
02
Core Thesis Monitors
Every Quarter · Non-Negotiable
| Signal |
Current Status |
Green Threshold |
Amber Threshold |
Red Threshold · Action |
| LatAm revenue growth (INR) |
+10% YoY |
>12% YoY |
6–12% — check if currency drag or volume weakness |
<6% for 2 quarters → formal thesis review |
| EBITDA margin |
35.0% |
>30% |
27–30% — identify cause (R&D spike vs structural) |
<27% sustained 2 quarters → thesis killer signal |
| Receivable days (LatAm proxy) |
~8–12 days est. |
<15 days — structural hedge intact |
15–25 days — credit extension in volatile markets |
>25 days sustained → currency exposure rising materially |
| Debt on balance sheet |
₹0 |
Zero debt |
Any debt >₹200 Cr — understand purpose |
Debt >₹500 Cr without clear strategic rationale → escalate |
| US front-end revenue |
$8.7M cumul. |
$15M annualised by Q2 FY27 |
Flat for 2 quarters despite new ANDA launches |
Declining or USFDA warning letter → immediate review |
| ANDA approvals pace |
55 cumulative |
8–12 new approvals/year |
<6 approvals in a year — pipeline thinning? |
Zero approvals for 2 consecutive quarters post-inspection |
| Promoter holding direction |
70.6% stable |
Stable or increasing |
Declining below 68% — understand reason |
Sudden sale >3% in one quarter without disclosed rationale |
| Currency disclosure quality |
Explicit on concalls |
Management quantifies local vs INR growth gap |
No currency commentary when INR revenue decelerates |
Sustained silence on currency + margin compression together |
| Liquid assets (₹ Cr) |
₹2,459 Cr |
>₹2,000 Cr or growing |
₹1,500–2,000 Cr — track cash deployment |
<₹1,000 Cr without a disclosed acquisition rationale |
| USFDA inspection outcome |
4/4 EIRs — last: Aug 2024 (zero obs.) |
EIR with VAI or NAI classification |
Form 483 with observations — review severity |
Warning letter or OAI classification → immediate position review |
03
Thesis Pillar Status
Q3 FY26 Assessment
✓ Intact
LatAm Distribution Moat
22,000+ touchpoints, negative working capital model intact, top-3 position in core CA markets. No signs of competitive entry or market share erosion. Mexico and Chile expansion proceeding.
✓ Intact
Capital Allocation Discipline
₹2,459 Cr liquid, zero debt, all capex self-funded. January 2026 ANDA acquisition in-domain (injectables/ophthalmics). No governance red flags. KMP pay at 1.35% of PAT.
◑ Building
US Injectable Thesis
Structural assets in place (55 ANDAs, 5,610 end users, 4 clean FDA inspections). Revenue materialisation is the pending confirmation. $15M annualised by Q2 FY27 is the first inflection test.
✓ Intact
Earnings Compounding
TTM EPS ₹80.74, up from ₹70.56 in FY25. 10-year PAT CAGR at 29%. Q3 FY26 PAT +19% YoY. Growth trajectory fully intact. FY26E EPS ₹88–92.
✓ Intact
Succession Pipeline
Vivek Siddarth as COO, Dr. Sridhar Ganesan re-appointed MD Aug 2024. Paarthipan active. Watch for Vivek's first earnings call appearance as succession signal.
◑ Watch
LatAm Currency Stability
Argentina under IMF programme — improving but fragile. Mexico peso under USMCA uncertainty pressure. Structural hedge (receivables model) intact. Stabilisation is a tailwind, not a requirement.
04
US ANDA Pipeline Tracker
Updated as approvals announced
Total Approvals (cumulative)
55
Including 10 acquired ANDAs (Jan 2026). 54 filed independently.
Pipeline (filed, pending)
55+
Target for filing over next 4 years. Injectables, ophthalmics, oncology.
Products Launched (US)
29
Of 55 approved. Gap = 26 approved but not yet commercially launched.
End Users (US front-end)
5,610
Hospitals, pharmacies, clinics. Target: 10,000+ for inflection.
State Licences
49/50
Near-complete US coverage. 7 wholesale distributors, 24 hospital systems.
Recent Approvals (Q4 FY26)
3
Methylprednisolone (Jan), Desmopressin $26M mkt (Feb), Sodium Phosphates $67M mkt (Feb).
| Recent ANDA Event |
Date |
Product / Market Size |
Significance |
| ANDA Acquisition |
Jan 1, 2026 |
10 ANDAs (injectables + ophthalmics) · combined US market ~$473M |
First inorganic ANDA move — in-domain, niche markets, commercial intelligence signal |
| USFDA Approval |
Jan 27, 2026 |
Methylprednisolone Acetate Injectable Suspension |
Complex injectable, limited competition, adds to niche injectable portfolio |
| USFDA Approval |
Feb 24, 2026 |
Sodium Phosphates Injection · US market ~$67M |
Meaningful market size, hospital formulary product |
| USFDA Approval |
Feb 28, 2026 |
Desmopressin Acetate Injection · US market ~$26M |
Specialty injectable, low generic competition expected |
05
Quarterly Results Log
Add new entry within 48hrs of each result
Mix: LatAm/US/Africa
76/20/4%
US share growing
Key observations: Margin expansion to 35% is the standout — 200bps YoY while revenue grew only 10% confirms operating leverage in the model. US share at 20% (up from 15% two years ago) — directionally correct. LatAm at 76% steady — no currency drag flagged in this quarter. Liquid assets at ₹2,459 Cr, up from ₹1,984 Cr in Sep 2024 — cash compounding even during heavy capex cycle. No concerns. Thesis intact.
Revenue
—
Target: >₹560 Cr
EBITDA
—
Target: >₹168 Cr
Watch
US rev
First $15M test begins
Watch for Q4 FY26: (1) US front-end revenue — first quarter where the recently approved ANDAs (Desmopressin, Sodium Phosphates) could start contributing. (2) Mexico contribution — management has flagged Mexico as a high-focus market with 35+ filings; any Mexico revenue callout is a new data point. (3) Vivek Siddarth on the earnings call — any increased speaking role is a succession signal. (4) FY26 full-year EPS vs ₹88–92 range.
Q1 FY27
Revenue ___
OPM ___
PAT ___
US Rev ___
EPS TTM ___
Verdict ___
Q2 FY27
Revenue ___
OPM ___
PAT ___
US Rev ___
EPS TTM ___
Verdict ___
Q3 FY27
Revenue ___
OPM ___
PAT ___
US Rev ___
EPS TTM ___
Verdict ___
06
Position Sizing Signals
When to add, hold, or exit
Add / Increase Position
US Revenue Inflection
US annualised revenue crosses $15M by Q2 FY27. First confirmation that the ANDA portfolio is converting to revenue at scale. The market will likely re-rate the multiple from 21× toward 28–30× on this signal alone.
LatAm Currency Tailwind
Management quantifies local currency growth materially above INR growth — e.g. "volumes +18%, INR +22%" — indicating currency is now a tailwind. A stabilisation year could add 300–500bps to PAT growth. Add on the first quarter this is explicit.
Stock Price Correction Unrelated to Thesis
A 20–30% stock correction driven by LatAm macro headlines, broader market sell-off, or technical factors — with no deterioration in any core thesis monitor — is the highest-conviction add signal in this position.
Vivek Succession Signal
Vivek Siddarth appearing as primary spokesperson on an earnings call. Signals staged, deliberate succession — removes the biggest governance uncertainty and likely triggers re-rating from "founder risk" discount to "institutional quality" premium.
Reduce / Exit Position
USFDA Warning Letter on Caplin Steriles
Reduce position by 50% immediately. Do not sell entirely — assess whether LatAm earnings power is intact. If LatAm continues compounding and the warning letter is isolated to Steriles, the stock's decline will overshoot the fundamental damage. Re-evaluate within 30 days.
OPM Below 27% for Two Consecutive Quarters
Sustained margin compression below 27% indicates structural erosion of the LatAm distribution moat — either competitive entry, pricing pressure, or mix deterioration. This is not a one-time event. Begin formal exit if confirmed in a third quarter.
Out-of-Domain Capital Allocation
Any acquisition outside pharmaceuticals/healthcare, any acquisition above ₹500 Cr without disclosed financials, or any related-party transaction above ₹25 Cr. The 35-year capital discipline is the moat's foundation — one governance failure invalidates the track record premium.
LatAm Revenue Flat + US Revenue Flat Simultaneously
Both growth engines stalling at the same time — for two consecutive quarters — with no credible macro explanation (temporary currency, one-time destocking). This is the scenario where the compounding thesis is broken, not stressed.